NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 14 April 2021

**Location:** Via Zoom

## Committee members present

1. Professor Gary McVeigh [Chair] Present for all items
2. Dr Lindsay Smith [Vice Chair] Present for all items
3. James Avery Present for all items
4. Martin Bradley Present for all items
5. Dr Matt Bradley Present for all items
6. Professor Sofia Dias Present for all items
7. Professor Rachel Elliott Present for all items
8. Rebecca Harmston Present for all items
9. Chris Herring Present for all items
10. Dr Robert Hodgson Present for all items
11. Dr Megan John Present for all items
12. Dr Bernard Khoo Present for all items
13. Dr Guy Makin Present for all items
14. Professor David Meads Present for all items
15. Stella O’Brien Present for all items
16. Dr Rebecca Payne Present for all items
17. Professor Chris Parker Present for all items
18. Dr Brian Shine Present for all items
19. Baljit Singh Present for all items
20. Dr John Watkins Present for all items
21. Tony Wootton  Present for all items

## NICE staff present:

Ross Dent, Associate Director Present for items 1 to 2.2.2

Linda Landells, Associate Director Present for items 3 to 3.2.2

Louise Jafferally, Project Manager Present for items 1 to 2.2.2

Kate Moore, Project Manager Present for items 3 to 3.2.2

Sally Doss, Technical Adviser Present for items1 to 2.2.2

Caron Jones, Technical Adviser Present for items 3 to 3.2.2

Victoria Gillis-Elliott, Technical Analyst Present for items 1 to 2.2.2

Luke Cowie, Technical Analyst Present for items 3 to 3.2.2

Nigel Gumbleton, Technical Analyst Present for all items

Sarah Bromley, Senior Medical Editor Present for items 1 to 2.2.2

Ann Greenwood, Senior Medical Editor Present for items 3 to 3.2.2

Emily Eaton Turner, Technical Adviser, Commercial Risk Assessment Team Present for all items

Ella Livingstone, Technical Adviser, Commercial Risk Assessment Team  
Present for all items

Mandy Tonkinson, Adviser, PIP Present for all items 1 to 2.1.3

Catherine Pank, Assistant Project Manager, COT Present for items 3 to 3.2.2

Gemma Smith, Coordinator, COT Present for all items

Lucinda Evans, Coordinator, MIP Present for all items

Sandra Robinson, Coordinator, MIP Present for items 1 to 2.1.3

Celia Mayers, Administrator, TA Present for items 3 to 3.2.2

Pratit Shah, Administrator, TA Present for items 1 to 2.2.2

## External group representatives present:

David Cooper, Aberdeen HTA Group Present for items 1 to 2.1.3

Dwayne Boyers, Aberdeen HTA Group Present for items 1 to 2.1.3

Claire Rothery, Centre for Reviews and Dissemination and Centre for Health Economics – York, Present for items 3 to 3.1.3

Mark Corbett, Centre for Reviews and Dissemination and Centre for Health Economics - York Present for items 3 to 3.1.3

## Clinical & patient experts present:

Dr Alison Birtle, Consultant Clinical Oncologist, clinical expert nominated by Fight Bladder Cancer, Present for items 1 to 2.1.3

Professor Peter Clark, CDF Clinical Lead, NHS England Present for items 1 to 2.1.3

Kevin Gorman, Patient expert nominated by Action Bladder Cancer UK Present for items 1 to 2.1.3

Professor Syed A Hussain, Professor of Medical Oncology, clinical expert nominated by Merck Serono Ltd Present for items 1 to 2.1.3

Dr Lydia Makaroff, Patient expert nominated by Fight Bladder Cancer Present for items 1 to 2.1.3

## Introduction to the meeting

* 1. The chair Dr Lindsay Smith welcomed members of the committee and other attendees present to the meeting.

### Appraisal of avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy [ID3735]

## Part 1 – Open session

* + 1. The chair welcomed the invited clinical & patient experts, external group representatives, members of the public and company representatives from Merck Serono.
    2. The chair asked all committee members, clinical & patient experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr Alison Birtle declared a financial interest as she has received advisory board fees and speaker fees from Sanofi-Genzyme and Bayer, Astellas, BMS and Pfizer, speaker fees from Janssen Pharmaceutical, Merck Sharp & Dohme and Roche and has provided educational support to Janssen Pharmaceutical and received research support from Sanofi-Genzyme.
* It was agreed that her declaration would not prevent Dr Birtle from providing expert advice to the committee.
* Kevin Gorman declared a financial interest as Action Bladder Cancer UK is expecting to receive a potential contribution from Merck [and others] to help compensate for loss of general income during the coronavirus pandemic.
* It was agreed that his declaration would not prevent Mr Gorman from providing expert advice to the committee.
* Professor Syed A Hussain declared a financial interest as he has received research funding from CR UK, MRC/NIHR, UHB charities, CCC charities, North West Cancer Research, Bayer, Janssen, Boehringer Ingelheim, Pierre Fabre and Eli Lilly and attended advisory boards and received consultancy fees from Roche, MSD, AstraZeneca, BMS, Janssen, GSK, Astellas, Pfizer, Bayer, Pierre Fabre, Ipsen and Sotio.
* It was agreed that his declaration would not prevent Professor Hussain from providing expert advice to the committee.
* Dr Lydia Makaroff declared a financial interest as Fight Bladder Cancer received a £1,000.00 Honorarium for expert input provided during the Virtual Global Patient Advisory Board on Bladder Cancer on 9th July 2020 from Merck Healthcare KGaA.
* It was agreed that her declaration would not prevent Dr Makaroff from providing expert advice to the committee.
* No further conflicts were declared for this item.
  + 1. The Chair introduced the lead team Professor Rachel Elliott, Rebecca Harmston and Professor Chris Parker, who gave presentations on the clinical effectiveness and cost effectiveness of avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy.
  1. Part 2 – Closed session [company representatives, clinical & patient experts, external group representatives and members of the public were asked to leave the meeting]
     1. The committee then agreed on the content of the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD]. The committee decision was reached by consensus..
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD] in line with their decisions.

### Appraisal of guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs [ID1658]

* 1. Part 1 – Open session
     1. The chair Professor Gary McVeigh welcomed the invited external group representatives, members of the public and company representatives from Janssen.
     2. The chair asked all committee members, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Professor Sofia Dias declared a non-financial professional & personal interest as she is part of the York ERG although it was confirmed she was not directly involved with this assessment.
* It was agreed that her declaration would not prevent Professor Dias from participating in this section of the meeting.
* Professor David Meads declared a non-financial professional & personal interest as the University of Leeds has received funding from Janssen, Abbvie, BMS, Sanofi and Celgene for research in an unrelated area.
* It was agreed that his declaration would not prevent Professor Meads from participating in this section of the meeting.
* Professor Chris Parker declared a financial interest as he has received speaker fees from Janssen for presentation at two educational meetings within last 12 months.
* It was agreed that his declaration would not prevent Professor Parker from participating in this section of the meeting.
* No further conflicts of interest were declared for this item.
  + 1. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document [ACD] received from consultees, commentators and through the NICE website.

## Part 2 - Closed session [company representatives, external group representatives and members of the public were asked to leave the meeting].

* + 1. The committee then agreed on the content of the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD]. The committee decision was reached by consensus..
    2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD] in line with their decisions.

## Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Wednesday 12 May 2021 and will start promptly at 9.30am.